1. Home
  2. Product Information
  3. Motilin Receptor Agonist

Product Information

Motilin Receptor Agonist

Compound Code RQ-00201894
Primary Target Indications GI motility disorders (gastroparesis, post-operative Ileus, and functional dyspepsia, etc.)
Development Stage Pre-clinical
Portfolio for global development, manufacturing, and marketing rights
Product Summary Motilin is a GI peptide hormone that regulates migrating motor contractions of the GI tract, thereby playing a crucial role in maintaining gut homeostasis. This compound is an orally-bioavailable small molecule with the strongest agonistic activity and highest selectivity at the motilin receptor among the compounds currently in development. Moreover, RQ-00201894 markedly improved hypo-motility in a dog model of gastric motor dysfunction by oral administration. The motilin receptor agonist is expected to be a breakthrough drug and meet an unsatisfied medical need for treatments of gastroparesis, postoperative ileus, functional dyspepsia and other diseases caused by gastrointestinal motility disorder.

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Press Release
Research & Development
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release